ESTRO 2024 - Abstract Book

S1441

Clinical - Head & neck

ESTRO 2024

The HNCIG omega score predicts relative risk of cancer vs competing risks and treatment allocation. The omega score represents an attractive candidate biomarker to define groups of patients with p16-positive oropharynx cancer for treatment de-escalation.

Keywords: Oropharynx, competing events, de-escalation

References:

1. Mehanna H et al. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. JCO, 2020: 38:2552-2557

2. Vitzthum L et al. Selection of Head and Neck Cancer Patients for Intensive Therapy, 2019: 106;1:157-166

2. Zakeri et al. Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020: 15;126(24):5263 5273

2986

Digital Poster

Does altered Body image have a link with impaired sexuality in Patients with Head and Neck cancers?

Nejla Fourati, Ahmed Jribi, Fatma Dhouib, Wafa Mnejja, Jamel Daoud

Habib Bourguiba Hospital Faculty of Medicine University of Sfax, Radiotherapy Department, Sfax, Tunisia

Purpose/Objective:

The concepts of altered body image and sexual health seem to be interrelated and often intertwined in patients with head and neck cancers (HNC). However, their link has rarely been studied in the literature.

This study aimed to establish the link between altered body image and impaired sexual health in patients with HNC interviewed at different times during cancer treatment.

Material/Methods:

This was a mono-centric descriptive cohort study assessing body image and sexual health in adult patients with HNC using the Body Image Scale (BIS) and the EORTC Sexual Health Questionnaire scale (EORTC SHQ-C22) respectively. Forty patients were included. All patients were married and leading a sexual life. The mean age was 52 years old [28-75] with a sex ratio of 3.4. Nasopharyngeal carcinoma and stage III were the most common (24 patients (60%) and 32 patients (80%) respectively). The questionnaires were led during treatment for 25 patients (62.5%) and before treatment for 13 patients (32.5%). Treatment included surgery for 7 patients (17.5%), chemotherapy for 27 patients (67.5%), radiotherapy for 29 patients (72.5%) and multimodal therapy for 18 patients